Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Completed · Phase 2 · NCT05771428
Conditions: Alzheimer's Disease (AD)
At a glance
- Research payments reported, 2025
- $128,630
- U.S. investigators named
- 20
- Sites paid
- 23
- Planned or actual enrollment
- 263
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-552 (drug), Placebo for ABBV-552 (drug)
- Dates
- Started 2023-06-05; completion 2024-09-12
- Results posted
- Yes
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. This study will assess how safe and effective ABBV-552 is in treating symptoms of early AD. Adverse events, change in disease activity, how ABBV-552 moves through body of participants and the body response to ABBV-552 will be assessed. ABBV-552 is an investigational dr…
From ClinicalTrials.gov, last updated 2025-10-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $128,630 in research payments for this study in 2025 (45 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Elly R. Lee, MD Psychiatry · Irvine, CA
- Peter J. Mcallister, M.D. Neurology · Fairfield, CT
- Aliuska Alvarez, MD Neurology · Miami, FL
- Jorge J. Calle Medina, M.D. Internal Medicine · Palm Springs, FL
- Rekha Gandhi, MD Neurology · Winter Park, FL
- Dunia Llapur Hernandez, MD Internal Medicine · Miami, FL
- Michael M. Pfeffer, MD Neurology · Miami, FL
- Beth E. Safirstein Neurology · Hallandale Beach, FL
- Lourdes M. Selem, MEDICAL DOCTOR Psychiatry · Miami Lakes, FL
- Kristi K. George, MD Neurology · Indianapolis, IN
- James C. Stevens, MD Neurology · Fort Wayne, IN
- Gregory A. Jicha, MD Neurology · Lexington, KY
- Eric J. Carbonell, M.D. Psychiatry · Festus, MO
- Michael D. Rosenberg, M.D. Radiology · Durham, NC
- Antonela Svetic, MD Neurology · Beavercreek, OH
- Joel Vandersluis, M.D. Neurology · Dayton, OH
- Hareshkumar D. Boghara, M.D. Family Medicine · Desoto, TX
- Aamr A. Herekar, M.D. Neurology · El Paso, TX
- Diana R. Kerwin, MD Geriatric Medicine · Dallas, TX
- Daniel A. Cohen, M.D. Neurology · Norfolk, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Conquest Research LLC $25,533
- Anesc Research $23,000
- Irvine Center for Clinical Research $17,812
- Ki Health PArtners LLC $15,530
- Sentara Leigh Hospital, VA $13,809
- Kerwin Memory Center LLC $10,586
- Allied Biomedical Research Institute $6,127
- Neurology Diagnostics Inc $2,824
- American Clinical Research Institute LLC $2,636
- New Life Medical Research Inc $2,000
- Ivetmar Medical Group $2,000
- Velocity Clinical Research Inc $1,800
- Allied Physicians Inc $1,577
- Finlay Medical Research Corp $1,500
- Wr-Pri LLC $1,200
- Epic Medical Research $155
- University of Kentucky College of Medicine $77
- New Life Medical Research Center $77
- Finlay Medical Research Corporation $77
- Ivetmar Medical Group LLC $77
- Interspond LLC $77
- New Horizon Research Center $77
- Jwm Neurology $77
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.